Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma
Phase 1
- Conditions
- Myeloma, Multiple
- Interventions
- Drug: Treat Regimen
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 18
- Registration Number
- NCT03150316
- Locations
- 🇰🇷
Samsung Hospital, Seoul, Gangnam-gu, Korea, Republic of
🇰🇷the catholic university of korea, Seoul ST. Mary's Hospital, Seoul, Seocho, Korea, Republic of
A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.
Phase 1
- Conditions
- Colorectal Cancer
- Interventions
- Drug: CKD-516 Tablet
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT03076957
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients
Phase 4
Completed
- Conditions
- Osteoarthritis Hand
- Interventions
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 117
- Registration Number
- NCT03067194
- Locations
- 🇰🇷
Soon Chun Hyang University Hospital, Seoul, Korea, Republic of
Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily
Phase 2
- Conditions
- Glaucoma, Primary Open AngleOcular Hypertension
- Interventions
- Drug: D565H(Latanoprost 25㎍/㎖)Drug: D565(Latanoprost 50㎍/㎖)
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 98
- Registration Number
- NCT03067415
- Locations
- 🇰🇷
Seoul National University Hosipital, Seoul, Jongno, Korea, Republic of
Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure
- Conditions
- Essential HypertensionChronic Stable AnginaCongestive Heart Failure
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 20000
- Registration Number
- NCT03063697
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 18
- Registration Number
- NCT03051841
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
The Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: D930, D565
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 15
- Registration Number
- NCT03034486
- Locations
- 🇰🇷
Dong-A University Hospital, Seo-gu, Busan, Korea, Republic of
Pharmacokinetic Drug-drug Interaction of CKD-330 and D086
Phase 1
Completed
- Conditions
- HypertensionHyperlipidemias
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 83
- Registration Number
- NCT03017950
- Locations
- 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 62
- Registration Number
- NCT02977065
- Locations
- 🇦🇺
Not provided, Adelaide, Australia
Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: CKD-519 200mgDrug: Placebo
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT02916901
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu 120-752, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath